Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening

Drug, Healthcare and Patient Safety

Volumn 4, Issue 1, 2012, Pages 167-172

  Naryshkin, Sonya ^a   Marshall Austin, R ^b  

^a MERCY HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cervical screening; HPV; Hybrid Capture 2; LDT; SurePath

Indexed keywords

VIRUS DNA;

ADULT; CANCER SCREENING; CASE REPORT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DNA DETERMINATION; FALSE NEGATIVE RESULT; FEMALE; HIGH RISK HUMAN PAPILLOMAVIRUS LABORATORY DEVELOPED TESTING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KOILOCYTOSIS; LYMPH NODE DISSECTION; OVARIECTOMY; PAPANICOLAOU TEST; PATIENT SAFETY; POLYMERASE CHAIN REACTION; RADICAL HYSTERECTOMY; REVIEW; SALPINGECTOMY; SMOKING; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CONIZATION; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE;

EID: 84869211117     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/dhps.s37273     Document Type: Review

References (38)

1. Wright TC Jr, Cox JT, Massad LS, et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287(16):2120-2129.
2. US Food and Drug Administration. FDA news: FDA approves expanded use of HPV test. FDA News. March 31, 2003. Available from: http://www.fda.gov/ohrms/dockets/dockets/07p0210/07p-0210-ccp0001-01-FDA-News-vol3.pdf. Accessed August 9, 2012.
3. Saslow D, Solomon D, Lawson H W, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516-542.
4. Vance GH. College of American Pathologists proposal for the oversight of laboratory-developed tests. Arch Pathol Lab Med. 2011; 135(11):1432-1435.
5. Clavel C, Masure M, Putaud I, et al. Hybrid Capture II, a new sensitive test for human papillomavirus detection. Comparison with Hybrid Capture I and PCR results in cervical lesions. J Clin Pathol. 1998;51(10):737-740.
6. Siddiqui MT, Cohen C, Nassar A. Detecting high-grade cervical disease on ASC-H cytology: role of BD ProEx C and digene Hybrid Capture II HPV DNA testing. Am J Clin Pathol. 2008;130(5):765-770.
7. Ko V, Tambouret RH, Kuebler DL, Black-Schaffer WS, Wilbur DC. Human papillomavirus testing using Hybrid Capture II with SurePath collection: initial evaluation and longitudinal data provide clinical validation for this method. Cancer. 2006;108(6):468-474.
8. TriPath Imaging. Comments on the FDA review of Digene's PMA application [press release]. Burlington, NC: TriPath Imaging; July 10, 2002.
9. Kupfer C, Lindebaum K, Giles J, Chendvankar R, Lee Y, Sprenger-Haussels M. QIAsymphony AXpH sample preparation for automated conversion of liquid-based cytology specimens for use in the digene HC2 high-risk HPV DNA test. Paper presented at: EUROGIN 2011 Congress; May 8-11, 2011; Lisbon, Portugal.
10. Belinson JL, Wu R, Belinson SE, et al. A population-based clinical trial comparing endocervical high-risk HPV testing using Hybrid Capture 2 and Cervista from the SHENCAST II study. Am J Clin Pathol. 2011;135(5):790-795.
11. Stoler MH, Wright TC Jr, Sharma A, et al. The interplay of age strati-fcation and HPV testing on the predictive value of ASC-US cytology. Am J Clin Pathol. 2012;137(2):295-303.
12. Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 assay but more specifc at detecting cervical precancer and cancer. J Clin Microbiol. 2011;49(2):557-564.
13. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah K V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55(4):244-265.
14. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens - part B: biological agents. Lancet Oncol. 2009;10(4):321-322.
15. Ferris RL, Martinez I, Sirianni N, et al. Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis. Eur J Cancer. 2005;41(5):807-815.
16. Kinney W, Fetterman B, Cox JT, Lorey T, Flanagan T, Castle PE. Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. Gynecol Oncol. 2011;121(2):309-313.
17. Kang WD, Kim CH, Co MK, et al. Comparison of Hybrid Capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions. Int J Gynecol Cancer. 2009;19(5):924-928.
18. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Signifcance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst. 2002;94(2):102-107.
19. Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV tests. Am J Clin Pathol. 2010; 135(2):193-199.
20. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100(7):492-501.
21. Boulet GA, Benoy IH, Depuydt CE, et al. Human papillomavirus 16 load and E2/E6 ratio in HPV16-positive women: biomarkers for cervical intraepithelial neoplasia $ 2 in a liquid-based cytology setting. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2992-2999.
22. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663-672.
23. Li Z, Austin RM, Guo M, Zhao C. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma. Arch Pathol Lab Med. August 20, 2012; [Epub ahead of print.]
24. Moelans CB, Oostenrijk D, Moons MJ, van Diest PJ. Formaldehyde substitute fxatives: effects on nucleic acid preservation. J Clin Pathol. 2011; 64(11):960-967.
25. Cuschieri KS, Beattie G, Hassan S, Robertson K, Cubie H. Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology medium. J Virol Methods. 2005;124(1-2):211-215.
26. Lin WM, Ashfaq R, Michalopoulos EA, Maitra A, Gazdar AF, Muller C Y. Molecular Papanicolaou tests in the twenty-frst century: molecular analyses with fluid-based Papanicolaou technology. Am J Obstet Gynecol. 2000;183(1):39-45.
27. Powell N, Smith K, Fiander A. Recovery of human papillomavirus nucleic acids from liquid-based cytology media. J Virol Methods. 2006;137(1):58-62.
28. Arbyn M, Andersson K, Bergeron C, Bogers J P, von Knebel-Doebertitz M, Dillner J. Cervical cytology biobanks as a resource for molecular epidemiology. Methods in Mol Biol. 2011;675:279-298.
29. SurePath® collection [package insert]. Franklin Lakes, NJ: Becton, Dickinson and Company; 2011.
30. Anekella B, Dryga S, Moskowitz K, et al. Stability of integrated HPV16 DNA in various sample transport media. J Mol Diagn. 2007;9:679-680.
31. ® 372 series 400 HPV DNA positive control. Available from: http://www.seracarecatalog.com/Default.aspx?tabid=219&txtSearch=A3&List=1&SortField=Produ ctName%2CProductName&ProductID=121#LiveContent[ACC-P]. Accessed July 16, 2012.
32. Moriarty AT, Bentz JS, Winkler B, et al. Profciency testing of high risk human papillomavirus DNA tests: the frst 3 years of experience of the College of Pathologists CHPV surveys. Arch Pathol Lab Med. Forthcoming 2012.
33. Davis-Devine S, Day SJ, Freund GG. Test performance comparison of inform HPV and Hybrid Capture 2 high-risk DNA test using the SurePath liquid-based Pap test as the collection method. Am J Clin Pathol. 2005;124(1):24-30.
34. Siddiqi A, Spataro M, McIntire H, et al. Hybrid capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined signifcance Papanicolaou results in SurePath and ThinPrep specimens. Cancer. 2009;117(5):318-325.
35. Zhao FH, Hu SY, Bian JJ, et al. Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China. Cancer Cytopathol. 2011;119(6):387-394.
36. Kelly RS, Patnick J, Kitchener HC, Moss SM. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer. 2011;105(7):983-988.
37. Stoler MH, Castle PE, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007; 127(3):335-337.
38. Naryshkin S, Austin RM. Limitations of widely used high risk HPV DNA testing in patients with invasive cervical cancer. Paper presented at: EUROGIN 2011 Congress; May 8-11, 2011; Lisbon, Portugal.